Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Aug 11, 2022
Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Aug 11, 2022
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation Aug 11, 2022
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Aug 09, 2022
Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022 Aug 03, 2022
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency Jul 27, 2022
Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia Jun 22, 2022
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma Jun 16, 2022
Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy Jun 13, 2022
